Skip to content

Healthy Adult Male Facial Skin Surface Lipid Pheromone p.o. to Treat Opioid Addiction

The Nicholson Science Pheromone Trial

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03394911
Enrollment
500
Registered
2018-01-09
Start date
2020-12-31
Completion date
2021-11-30
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Opioid Abuse, Opioid Abuse, Continuous Use, Opioid Abuse, Episodic, Opioid Addiction, Opioid Dependence, Opioid Intoxication, Opioid-Related Disorders, Opioid Use, Opioid-use Disorder, Paternal Pheromone Deficiency

Brief summary

Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth. Elevated mood eventually becomes accommodated after a few weeks. The pheromone contains volatile airborne sub-pheromones which cause aversive behavior (distrust, superstition, suspicion, arrogance, astonishment/stupidity, jealousy). Artificial jealousy can be avoided by patient isolation for 40 days until the pheromone taste wears off the saliva. The pheromone provided is odorless, colorless, and tasteless to the conscious brain.

Detailed description

Healthy adult human male facial skin surface lipid liquid pheromone given by mouth to opioid addicts cures them without any withdrawal symptoms whatsoever 250mg on chewing gum vehicle by mouth. Elevated mood eventually becomes accommodated after a few weeks. The pheromone contains volatile aversive sub-pheromones which cause aversive behavior (distrust, superstition, suspicion, arrogance, astonishment/stupidity, jealousy). Artificial jealousy can be avoided by patient isolation for 40 days until the pheromone taste wears off the saliva. The pheromone provided is odorless, colorless, and tasteless to the conscious brain. Pheromone action is insidious. The lifting of the appetite for addictive drugs monkey on the back feeling is gratifying. Ambition returns and ambitions are realized. To mitigate aversive airborne sub-pheromone methyl esters (almost certainly the cause of artificial aversive emotions), we will be trying several attenuation strategies. Staff collecting, storing, and dispensing pheromone (and placebo) will utilize the provided 3M Versaflo supplied air carbon filtered respirator for pharmaceutical applications. Collection from volunteer pheromone donors and administration to tox screened opioid addicts will be in areas ventilated by Dyson carbon-filtered oscillating fans placed to break up plumes of airborne sub-pheromone sufficiently to attenuate aversive emotion. Other lab techniques will also be tried as artificially stimulated emotional and heartfelt complaints are expected, from everybody. Unfortunately, the rapid process of healing opioid addiction will involve the unavoidable creation of potentially problematic emotions. We will try smaller daily doses, reverse Fisher esterification with apple cider vinegar, more vigorous air disturbances, negative air pressure, fume hoods, isolation, etc.

Interventions

BIOLOGICAL250mg healthy adult male facial skin surface lipid liquid pheromone

Human Pheromone provided p.o. to tox-screen verified opioid drug addict

Sponsors

Tampa General Hospital
CollaboratorOTHER
Otrimed Clinical Research
CollaboratorOTHER
Bubba Nicholson
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

Identical packaging, identical labeling, identifying random numbers in key onsite with pharmaceuticals technician on site. Identical vehicle. Pheromone is odorless, colorless, tasteless. Placebo handled exactly as Pheromone/experimental, but without application of pheromone.

Intervention model description

Double-blind, cross-over, placebo-controlled clinical trial in hospital setting overseen by attending physician, χ2 test for categorized data

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Dirty Tox Screen showing recent and continuing opioid drug dependence -

Exclusion criteria

Pregnant people, people who desire to retain their paraphilia \-

Design outcomes

Primary

MeasureTime frameDescription
Clean Tox Screen, UDS, urinary drug screensix weeks, all common opioids clear in six weeks time. Cannabis may take a little longer than six weeks to clear, but we are not really interested in that, are we?no drug use since pheromone provided. Urinary Drug Screens are among the most common medical tests in hospitals. Positive or Dirty urinary drug screens are routinely followed up with gas chromatography--mass spectrometry to assure test results.
Dirty Tox Screensix weeks, all common opioids clear in six weeks time. Cannabis may take a little longer than six weeks to clear, but we are not really interested in that, are we?Continued heavy drug use comparable to initial Tox Screen testing. Urinary Drug Screens are among the most common medical tests in hospitals. Positive or Dirty urinary drug screens are routinely followed up with gas chromatography--mass spectrometry to assure test results.

Contacts

Primary ContactBubba Nicholson
info@NicholsonScience.com(813) 259-1438
Backup ContactRoss C Nicholson
TogetherinParis@gmail.com(813) 259-1438

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026